Table 2.
Ongoing clinical trials involving CDK inhibitors in ER+ breast cancer
| Target | Compound | NCT number | Population |
|---|---|---|---|
| CDK | Ribociclib, Hormone therapy | NCT03285412 | Adjuvant ER+ |
| Ribociclib, Hormone therapy | NCT03078751 | ||
| Ribociclib, Hormone therapy | NCT03081234 | ||
| Palbociclib, Anastrozole, Goserelin | NCT01723774 | ||
| Abemaciclib | NCT02831530 | ||
| Chemotherapy or Ribociclib and Letrozole | NCT03283384 | Neoadjuvant ER+ | |
| Fulvestrant with or without Palbociclib | NCT03447132 | ||
| Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor | NCT02603679 | ||
| + Palbociclib, Goserelin + Aromatase Inhibitor + Palbociclib | |||
| Palbociclib, Hormone therapy | NCT01864746 | ER+ post-neoadjuvant | |
| Ribociclib, Letrozole | NCT03439046 | ER+ MBC | |
| Ribociclib, Letrozole | NCT01958021 | ||
| Ribociclib, Letrozole, Goserelin | NCT02941926 | ||
| Ribociclib, Fulvestrant | NCT02422615 | ||
| Endocrine therapy plus CDK 4/6 | NCT03425838 | ||
| Ribociclib, Letrozole, Goserelin | NCT03096847 | ||
| Ribociclib or Palbociclib, Fulvestrant | NCT02632045 | ||
| Palbociclib, Letrozole | NCT02499146 | ||
| Palbociclib, hormone therapy | NCT02040857 | ||
| G1T38 with Fulvestrant | NCT02983071 | ||
| Letrozole alone or with Palbociclib | NCT00721409 | ||
| Palbociclib, hormone therapy | NCT03184090 | ||
| Palbociclib, Letrozole | NCT01740427 | ||
| Palbociclib, Exemestane, Goserelin | NCT02917005 | ||
| Palbociclib, Letrozole | NCT02297438 | ||
| Palbociclib | NCT03159195 | ||
| Palbociclib, Tamoxifen | NCT02668666 | ||
| Aromatase inhibitor, Palbociclib | NCT03439735 | ||
| Palbociclib and aromatase inhibitor or Palbociclib and Fulvestrant | NCT03220178 | ||
| Exemestane plus Goserelin with Palbociclib versus Capecitabine | NCT02592746 | ||
| Abemaciclib, Fulvestrant | NCT02107703 | ||
| Abemaciclib | NCT02763566 | ||
| Palbociclib, Letrozole | NCT01684215 | ||
| CDK, HER2 | Palbociclib, Letrozole, Trastuzumab, Goserelin | NCT02907918 | Neoadjuvant ER+/HER2+ |
| Ribociclib with Trastuzumab or Trastuzumab emtansine | NCT02657343 | ER+/HER2+ MBC | |
| Tucatinib in combination with Palbociclib and Letrozole | NCT03054363 | ||
| CDK, PD-1 | Ribociclib, PDR001, Fulvestrant | NCT03294694 | ER+ MBC |
| CDK, IGF | Xentuzumab, Abemaciclib, Fulvestrant | NCT03099174 | ER+ MBC refractory to CDK4/6 |
| CDK, FGFR | Erdafitinib, Palbociclib, Fulvestrant | NCT03238196 | FGFR-amplified ER+ |
MBC, metastatic breast cancer; PD-1, programmed cell death protein 1; IGF, Insulin Growth Factor; FGFR, Fibroblast Growth Factor Receptor. Table updated from clinicaltrials.gov on March 11, 2018.